Skip to content

A Study of Radiotherapy Planning System Software ---- Zeus Cloud

A Multicenter Study on the Feasibility of a Radiotherapy Treatment Planning System (TPS) Software---Zeus Cloud

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04579718
Enrollment
63
Registered
2020-10-08
Start date
2020-11-01
Completion date
2022-10-31
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiotherapy

Keywords

Treatment Planning System

Brief summary

To evaluate the feasibility of Zeus Cloud TPS in the design of photon intensity modulated radiation therapy (IMRT) plan for tumors in various parts of the body.

Detailed description

This is a self-control, multi-center non-inferiority study. Subjects meeting inclusion criteria have radiation treatment plans designed by Zeus Cloud TPS and Eclipse treatment planning software from Varian, respectively. The qualities of two plans are compared. This is a observational study as the two plans are not executed.

Interventions

OTHERZeus Cloud TPS V1.0

Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.

OTHEREclipse

Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.

Sponsors

The First Affiliated Hospital of Soochow University
CollaboratorOTHER
The Affilicated Suzhou Science and Technology Town Hospital
CollaboratorUNKNOWN
Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with confirmed brain glioma, nasopharyngeal carcinoma, lung cancer, esophageal cancer, gastric cancer, liver cancer, prostate cancer, cervical cancer and rectal cancer; 2. The medical imaging data (CT) of the subjects were complete and available; 3. Between 18 and 75 years old, regardless of gender;

Exclusion criteria

1. The patients had metal implants; 2. Not suitable for clinical trials judged by investigators.

Design outcomes

Primary

MeasureTime frame
The qualification rate of treatment plans based on dosimetry2 months

Secondary

MeasureTime frame
The conformability index of radiation dose to the target2 months
single-field pass rate2 months
composite-field pass rate2 months

Contacts

Primary ContactBo Qiu, MD
qiubo@sysucc.org.cn+86-020-87343031

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026